LAVA Therapeutics N.V.

NasdaqGS LVTX

LAVA Therapeutics N.V. Market Capitalization on January 14, 2025: USD 25.77 M

LAVA Therapeutics N.V. Market Capitalization is USD 25.77 M on January 14, 2025, a -40.12% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • LAVA Therapeutics N.V. 52-week high Market Capitalization is USD 105.77 M on March 26, 2024, which is 310.40% above the current Market Capitalization.
  • LAVA Therapeutics N.V. 52-week low Market Capitalization is USD 25.66 M on January 10, 2025, which is -0.43% below the current Market Capitalization.
  • LAVA Therapeutics N.V. average Market Capitalization for the last 52 weeks is USD 53.58 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NasdaqGS: LVTX

LAVA Therapeutics N.V.

CEO Mr. Stephen Allen Hurly M.B.A., M.Sc.
IPO Date March 26, 2021
Location Netherlands
Headquarters Yalelaan 60
Employees 37
Sector Health Care
Industries
Description

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

Similar companies

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

GBIO

Generation Bio Co.

USD 0.88

-4.35%

RZLT

Rezolute, Inc.

USD 4.72

-0.63%

TIL

Instil Bio, Inc.

USD 20.03

5.31%

ERAS

Erasca, Inc.

USD 1.93

-10.23%

XLO

Xilio Therapeutics, Inc.

USD 1.08

-1.82%

ADAG

Adagene Inc.

USD 1.80

1.12%

ASMB

Assembly Biosciences, Inc.

USD 14.74

-1.01%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

EWTX

Edgewise Therapeutics, Inc.

USD 27.52

8.65%

CCCC

C4 Therapeutics, Inc.

USD 3.74

6.86%

AVTE

Aerovate Therapeutics, Inc.

USD 2.47

-1.20%

ACRV

Acrivon Therapeutics, Inc. Common Stock

USD 5.56

0.91%

DSGN

Design Therapeutics, Inc.

USD 4.02

-2.19%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

PMVP

PMV Pharmaceuticals, Inc.

USD 1.35

-2.88%

StockViz Staff

January 15, 2025

Any question? Send us an email